References
- Sanmartín M, Bellmunt S, Cosín-Sales J, García-Moll X, Riera-Mestre A, Almendro-Delia M, Hernández JL, Lozano F, Mazón P, Suarez Fernández C. Role of rivaroxaban in the prevention of atherosclerotic events. Expert Rev Clin Pharmacol. 2019;12(8):1–12. doi:https://doi.org/10.1080/17512433.2019.1637732.
- Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation. 2020;7:142(1):40–48. doi:https://doi.org/10.1161/CIRCULATIONAHA.120.046048.
- Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–636. doi:https://doi.org/10.1161/CIRCRESAHA.115.306301.
- Bono F, Schaeffer P, Hérault JP, Michaux C, Nestor AL, Guillemot JC, Herbert JM. Factor Xa activates endothelial cells by a receptor cascade between EPR-1 and PAR-2. Arterioscler Thromb Vasc Biol. 2000;20(11):E107–12. doi:https://doi.org/10.1161/01.ATV.20.11.e107.
- Kaname S, Yosuke M, Toku S, Shintaro N, Jun T, Yasushi O, Toshihiro M, Shigeyuki N, Takaaki S. Demeanor of rivaroxaban in activated/inactivated FXa. J Pharmacol Sci. 2017;156–161:1347–8613.
- Daci A, Da Dalt L, Alaj R, Shurdhiqi S, Neziri B, Ferizi R, Danilo Norata G, Krasniqi S. Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models. PLoS ONE. 2020;15(12):e0240669. doi:https://doi.org/10.1371/journal.pone.0240669.
- Luchetti R, Crinelli E, Cesarini B, Canonico L, Guidi C, Zerbinati G, Di Sario L, Zamai M, Magnani S, Papa L. Iuliano,Endothelial cells, endoplasmic reticulum stress and oxysterols. Redox Biol. 2017;13:581–587. doi:https://doi.org/10.1016/j.redox.2017.07.014.
- Oikonomou E, Leopoulou M, Theofilis P, Antonopoulos AS, Siasos G, Latsios G, Mystakidi VC, Antoniades C, Tousoulis D. A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: clinical and therapeutic implications. Atherosclerosis. 2020;309:16–26. doi:https://doi.org/10.1016/j.atherosclerosis.2020.07.027.
- Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Nishimoto S, Yagi S, Yamada H, Soeki T, Wakatsuki T, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis. 2015;242(2):639–646. doi:https://doi.org/10.1016/j.atherosclerosis.2015.03.023.
- Woźniak E, Broncel M, Bukowska B, Gorzelak-Pabiś P. The protective effect of dabigatran and rivaroxaban on DNA oxidative changes in a model of vascular endothelial damage with oxidized cholesterol. Int J Mol Sci. 2020;21(6):1953. doi:https://doi.org/10.3390/ijms21061953.
- Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm. 2008;65:1520–1529. doi:https://doi.org/10.2146/ajhp070624.
- Chalubinski M, Zemanek K, Skowron W, Wojdan K, Gorzelak P, Broncel M. The effect of 7-ketocholesterol and 25-hydroxycholesterol on the integrity of the human aortic endothelial and intestinal epithelial barriers. Inflamm Res. 2013;62(12):1015–1023. doi:https://doi.org/10.1007/s00011-013-0660-x.
- Beer JH, Bonetti N. COMPASS to REACH the right patients with thrombocardiology: benefits, risks, and future of the new concept. Eur Heart J. 2018;39(9):758–761. doi:https://doi.org/10.1093/eurheartj/ehx702.
- Abola MTB, Golledge J, Miyata T, Rha SW, Yan BP, Dy TC, Ganzon MSV, Handa PK, Harris S, Zhisheng J, et al. Asia-Pacific consensus statement on the management of peripheral artery disease: a report from the Asian Pacific society of atherosclerosis and vascular disease Asia-Pacific peripheral artery disease consensus statement project committee. J Atheroscler Thromb. 2020;27(8):809–907. doi:https://doi.org/10.5551/jat.53660.
- Leonarduzzi G, Gamba P, Gargiulo S, Biasi F, Poli G. Inflammation‐related gene expression by lipid oxidation‐derived products in the progression of atherosclerosis. Free Radic Biol Med. 2012;52:19–34.
- Ou ZJ, Chen J, Dai WP, Liu X, Yang YK, Li Y, Lin ZB, Wang TT, Wu YY, Su DH, et al. 25-Hydroxycholesterol impairs endothelial function and vasodilation by uncoupling and inhibiting endothelial nitric oxide synthase. Am J Physiol Endocrinol Metab. 2016;311(4):E781–E790. doi:https://doi.org/10.1152/ajpendo.00218.2016.
- Álvarez E, Paradela-Dobarro B, Raposeiras-Roubín S, González-Juanatey JR. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium. Br J Clin Pharmacol. 2018;84(2):280–291. doi:https://doi.org/10.1111/bcp.13440.
- Puech C, Delavenne X, He Z, Forest V, Mismetti P, Perek N. Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin/PAR-1 pathway. Brain Res. 2019;1719:57–63. doi:https://doi.org/10.1016/j.brainres.2019.05.024.
- Shi M, Huang J, Sun X, Wang F, Chu X, Jiang R, Wang Y, Pang L. Effect of rivaroxaban on the injury during endotoxin-induced damage to human umbilical vein endothelial cells. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31(4):468–473.
- Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015;15:130. doi:https://doi.org/10.1186/s12872-015-0124-z.
- Kaneko T, Fujii S, Matsumoto A, Goto D, Makita N, Hamada J, Moriuchi T, Kitabatake A. Induction of tissue factor expression in endothelial cells by basic fibroblast growth factor and its modulation by fenofibric acid. Thromb J. 2003;1(1):6. doi:https://doi.org/10.1186/1477-9560-1-6.
- Khakpour S, Wilhelmsen K, Hellman J. Vascular endothelial cell toll-like receptor pathways in sepsis. Innate Immun. 2015;21(8):827–846. doi:https://doi.org/10.1177/1753425915606525.
- Ellinghaus P, Perzborn E, Hauenschild P, Gerdes C, Heitmeier S, Visser M, Summer H, Laux V. Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran. Thromb Res. 2016;142:44–51. doi:https://doi.org/10.1016/j.thromres.2016.04.008.
- Lampugnani MG. Endothelial cell-to-cell junctions: adhesion and signaling in physiology and pathology. Cold Spring Harb Perspect Med. 2012;2(10). doi:https://doi.org/10.1101/cshperspect.a006528.
- Noda K, Zhang J, Fukuhara S, Kunimoto S, Yoshimura M, Mochizuki N. Vascular endothelial-cadherin stabilizes at cell-cell junctions by anchoring to circumferential actin bundles through alpha- and beta-catenins in cyclic AMP-Epac-Rap1 signal-activated endothelial cells. Mol Biol Cell. 2010;21(4):584–596. doi:https://doi.org/10.1091/mbc.e09-07-0580.
- Sarelius IH, Glading AJ. Control of vascular permeability by adhesion molecules. Tissue Barriers. 2015;3(1–2):e985954. doi:https://doi.org/10.4161/21688370.2014.985954.
- Wu TC, Chan JS, Lee CY, Leu HB, Huang PH, Chen JS, Lin SJ, Chen JW. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2015;14:81. doi:https://doi.org/10.1186/s12933-015-0243-y.
- Stojkovic S, Kaun C, Basilio J, Rauscher S, Hell L, Krychtiuk KA, Bonstingl C, De Martin R, Gröger M, Ay C, et al. Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. Sci Rep. 2016;6:25171. doi:https://doi.org/10.1038/srep25171.
- Chen PJ, Wang YL, Kuo L-M, Lin CF, Chen CY, Tsai YF, Shen -J-J, Hwang T-L. Honokiol suppresses TNF-α-induced neutrophil adhesion on cerebral endothelial cells by disrupting polyubiquitination and degradation of IκBα. Sci Rep. 2016;6:26554. doi:https://doi.org/10.1038/srep26554.
- Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326. doi:https://doi.org/10.1089/jir.2008.0027.